Please assess the completion status of the following clinical trial:

Trial Title: NLA101 in Adults Receiving High Dose Chemotherapy for AML

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Criteria:~Inclusion Criteria:~* Age ≥ 18 (or legal age of majority for sites outside US).~* Untreated de novo or secondary acute myeloid leukemia (AML), including AML that has progressed from myelodysplastic syndrome (MDS), and histologically documented diagnosis~* Eligible for at least 2 cycles of standard of care AML chemotherapy that will result in moderate to severe myelosuppression and have curative intent~* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2 or Karnofsky Status of 50 to 100.~* Adequate cardiac, renal, and hepatic functions.~Exclusion Criteria:~* Extramedullary disease in the absence of bone marrow or blood involvement~* Acute promyelocytic leukemia (APL) with PML-RARA~* Prior AML therapy, with the exception of intrathecal chemotherapy or emergent radiation for myeloid sarcoma.~* Concurrent malignancy requiring active treatment with chemotherapy, immunotherapy, or radiation~* Prior allotransplant, including allogeneic hematopoietic cell transplant or solid organ allogeneic transplant~* Known hypersensitivity or history of hypersensitivity to dimethylsulfoxide (DMSO)~* Active/chronic human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV) infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control Arm (Type: OTHER): The Control Arm will receive standard of care (SOC) chemotherapy without the infusion of NLA101. SOC chemotherapy will be determined by local PI and must be a standard regimen for untreated de novo or secondary AML that will result in moderate to severe myelosuppression and will be given with curative intent.
- Low Dose Arm (Type: EXPERIMENTAL): The Low Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of low-dose NLA101.
- Medium Dose Arm (Type: EXPERIMENTAL): The Medium Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of medium-dose NLA101.
- High Dose Arm (Type: EXPERIMENTAL): The High Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of high-dose NLA101.

Based on this trial design, predict the completion outcome and termination type (if applicable).